ClinicalTrials.Veeva

Menu

Study of ZIO-201 in Advanced Sarcoma

Alaunos Therapeutics logo

Alaunos Therapeutics

Status and phase

Completed
Phase 2
Phase 1

Conditions

Advanced Sarcoma

Treatments

Drug: ZIO-201

Study type

Interventional

Funder types

Industry

Identifiers

NCT00439686
IPM2001

Details and patient eligibility

About

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced sarcoma.

Enrollment

54 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Metastatic and /or unresectable disease state after previous standard chemotherapy

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

54 participants in 2 patient groups

Phase 1: Palifosfamide-lysine 590 mg/m²
Experimental group
Description:
Participants received palifosfamide-lysine 590 mg/m² by intravenous infusion over approximately 15 minutes on Days 1, 2, and 3 of each 21-day cycle. Four participants were treated at this dose level. Dose escalation was discontinued after 2 of 4 participants experienced dose-limiting toxicities during Cycle 1.
Treatment:
Drug: ZIO-201
Phase 2: Palifosfamide-lysine 413 mg/m²
Experimental group
Description:
Participants received palifosfamide-lysine 413 mg/m² by intravenous infusion over approximately 15 minutes on Days 1, 2, and 3 of each 21-day cycle. Forty-nine participants were treated at this dose level. The last 6 participants enrolled also participated in a pharmacokinetic substudy in which they received a single dose of palifosfamide-tris 178 mg/m² on Day -14 before beginning palifosfamide-lysine treatment.
Treatment:
Drug: ZIO-201

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems